Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01215357Phase 2Completed

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Role: collaborator

NCT01751802Phase 3Terminated

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

Role: collaborator

NCT01408394Phase 1Completed

Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

Role: collaborator

NCT02102698Phase 2Completed

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Role: collaborator

NCT01244633Phase 1Completed

Ecopipam Treatment of Tourette Syndrome

Role: lead

NCT00958503Phase 1Completed

Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue

Role: lead

NCT01065558Phase 1Completed

Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Role: lead

All 7 trials loaded